MiRNA-501-3p and MiRNA-502-3p: A Promising Biomarker Panel for Alzheimer's Disease
INTRODUCTIONAlzheimers disease (AD) lacks a less invasive and early detectable biomarker. Here, we investigated the biomarker potential of miR-501-3p and miR-502-3p using different AD sources. METHODSMiR-501-3p and miR-502-3p expressions were evaluated in AD CSF exosomes, serum exosomes, familial and sporadic AD fibroblasts and B-lymphocytes by qRT-PCR analysis. Further, miR-501-3p and miR-502-3p expressions were analyzed in APP, Tau cells and media exosomes. RESULTSMiR-501-3p and miR-502-3p expressions were significantly upregulated in AD CSF exosomes relative to controls. MiRNA levels were high in accordance with amyloid plaque and NFT density in multiple brain regions. Similarly, both miRNAs were elevated in AD and MCI serum exosomes compared to controls. MiR-502-3p expression was high in fAD and sAD B-lymphocytes. Finally, miR-501-3p and miR-502-3p expression were elevated intracellularly and secreted extracellularly in response to APP and Tau pathology. DISCUSSIONThese results suggest that miR-501-3p and miR-502-3p could be promising biomarkers for AD.